Blood Type Linked to Outcomes of Immune Checkpoint Inhibitor Therapy in Metastatic Cancer - Cancer Therapy Advisor

Blood type may influence response to immune checkpoint inhibitor therapy among patients with metastatic cancer, a study suggests.

Blood type may influence response to immune checkpoint inhibitor (ICI) therapy among patients with metastatic cancer, according to a study published in The Oncologist.  The study suggests that type … [+2329 chars]

full article...